Shares of Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.36 and traded as high as $2.11. Microbot Medical shares last traded at $1.65, with a volume of 33,273,909 shares trading hands.
Analyst Ratings Changes
Separately, HC Wainwright lifted their target price on shares of Microbot Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, January 24th.
View Our Latest Stock Analysis on MBOT
Microbot Medical Price Performance
Microbot Medical (NASDAQ:MBOT – Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Research analysts predict that Microbot Medical Inc. will post -0.71 EPS for the current year.
Institutional Investors Weigh In On Microbot Medical
An institutional investor recently bought a new position in Microbot Medical stock. Renaissance Technologies LLC purchased a new stake in Microbot Medical Inc. (NASDAQ:MBOT – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 105,658 shares of the biotechnology company’s stock, valued at approximately $118,000. Renaissance Technologies LLC owned about 0.52% of Microbot Medical at the end of the most recent reporting period. Hedge funds and other institutional investors own 16.30% of the company’s stock.
Microbot Medical Company Profile
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Featured Articles
- Five stocks we like better than Microbot Medical
- Manufacturing Stocks Investing
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- Where to Find Earnings Call Transcripts
- Are Tariffs Threatening Disney’s Comeback Story?
- Trading Halts Explained
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.